A review of post-cardiopulmonary bypass bleeding, aminocaproic acid, tranexamic acid, and aprotinin

American Journal of Therapeutics

Volumn 3, Issue 12, 1996, Pages 821-838

  Barrons, Robert W ^a,c   Jahr, Jonathan S ^b  

^a Xavier University of Louisiana College of Pharmacy   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

cardiac surgery, blood conservation, aminocaproic acid, tranexamic acid, aprotinin.

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; PLASMIN; SERINE PROTEINASE; TRANEXAMIC ACID;

BLEEDING; BLOOD CLOTTING DISORDER; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE NECROSIS; MYOPATHY; NAUSEA; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW;

EID: 0030426190     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199612000-00007     Document Type: Review

References (122)

1. Goodnaugh LT, Johnston MF, Ramsey G, Sayers MH, Eisenstadt RS, Anderson KC, Rutman RC, Silberstein LE, et al.: Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 1990;50:675-683.
2. Woodman RC, Harker LA: Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76(9): 1680-1679.
3. Ratnatunga CP, Rees GM, Kovacs IB: Preoperative hemostatic activity and excessive bleeding after cardiopulmonary bypass. Ann Thorac Surg 1991;52:250-257.
4. DelRossi AJ, Cernaianu AC, Botros S, Lemole GM, Moore R: Prophylactic treatment of postperfusion bleeding using EACA. Chest 1989;96:27-30.
5. Walker RH: Award lectures and special reports: Transfusion risks. Am J Clin Pathol 1987;88:374-378.
6. Juji T, Shibata Y, Hirofumi I, Takayuki S, Takashi I, Shigeo M. Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989;320:56.
7. Scott WJ, Randolph K, Wernly JA: Blood conservation in cardiac surgery. Ann Thorac Surg 1990;50:843-851.
8. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ: Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56(5):824-834.
9. Voorhees ME, Elgas R: Membrane and bubble oxygenators. In: Techniques in Extracorpeal Circulation, 3rd ed. (Ed. Kay PH), Butterworth-Heinerman Ltd., United Kingdom 1993, pp. 42-55.
10. Edmunds LH, Salaman EW: Hemostatic problems, trans fusion therapy, and cardiopulmonary bypass in surgical patients. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. (Eds. Coleman RW, Hirsh J, Marder VJ, Salzman EW), JB Lippincott Company, Philadelphia, 1994, pp. 963-968.
11. Van Oeveren W, Kazatchkine MD, Descamps-Latscha B, Maillet F, Fischer E, Carpentier A, et al.: Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovac Surg 1985;89:888-899.
12. Barlett RH, Delius RE: Physiology and pathophysiology of extracorpeal circulation. In: Techniques in Extracorpeal Circulation, 3rd ed. (Ed. Kay PM), Butter-Heinerman Ltd., United Kingdom, 1993, pp. 8-32.
13. Van den Dugen JJAM, Karliczek GF, Brenken U, Van der Heide JNH, Wildevuur CRH: Clinical study of blood trauma during perfusion with membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982;83:108-116.
14. Shah MV: Priming fluids for cardiopulmonary bypass. In: Techniques in Extracorpeal Circulation, 3rd ed. (Ed. Kay PH), Butter-Heinerman Ltd., United Kingdom, 1993, pp. 72-77.
15. Mammen EF, Koets MH, Washington BC, Wolk LW, Brwon JM, Burdick M, et al.: Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985;11(3):281-292.
16. Bigi L, Ghelli N, Menghini A, Panzani I: Design and principles of extracorpreal circuit. In Techniques in Extracorpreal Circulation, 3rd ed. (Ed. Kay PH), ButterHeinerman Ltd., United Kingdom, 1993, pp. 33-41.
17. Kay PH: Low flow and circulatory arrest. In: Techniques in Extracorpeal Circulation, 3rd ed. (Ed. Kay PH), ButterHeinerman Ltd., United Kingdom, 1993, 230-235.
18. Valeri RC, Cassidy G, Khuri S, Feingold H, Ragno G, Altschule MD: Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987;205(2):175-181.
19. Yoshihara H, Yamamoto T, Mihara H: Changes in coagulation and fibrinolysis occurring in dogs during hypothermia. Thromb Res 1985;37:503-512.
20. Yau TM, Carson S, Weisel RD, Ivanov J, Sun Z, Yu R: The effect of warm heart surgery in postoperative bleeding. J Thorac Cardiovasc Surg 1992;103:1155-1163.
21. Kurrek MM, Reed RL: Effect of hypothermia on enzymatic activity of thrombin and plasmin. Surg Forum 1987;28:221-223.
22. Ulmas J, Gauvin G, Taff R: Heparin monitoring and neutralization during cardiopulmonary bypass using a rapid plasma separator and a fluorometric assay. Ann Thorac Surg 1984;37(4):301-303.
23. Culliford AT, Gitel SN, Starr N, Thomas ST, Bauman FG, Wessler S: Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981;193(1):105-111.
24. Rajah MS, Penny AF: Haematological aspects of extracorpreal circulation. In: Techniques in Extracorpeal Circulation, 3rd ed. (Ed. Kay PH), Butter-Heinerman Ltd., United Kingdom, 1993, 144-155.
25. Ellison N, Beatty CP, Blake DR, Wurzel HA, MacVaugh H: Heparin rebound. Studies in patients and volunteers. J Thorac Cardiovasc Surg 1974;67(5):723-729.
26. Pifarre R, Babka R, Sullivan HJ, Montoya A, Bakhos M, El-Etr A: Management of postoperative heparin rebound following cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981;81:378-381.
27. Jobes DR, Schwartz AJ, Ellison N: Heparin rebound. J Thorac Cardiovasc Surg 1981;82(6):940-941.
28. Gans H, Castaneda AR, Subramanian V, John S. Lillehei CW: Problems in hemostasis during open heart surgery: Changes observed in the plasminogen-plasmin system and their significance for therapy. Ann Surg 1967;166(6): 980-986.
29. Kevy SV, Glickman RM, Bernhard WF, Diamond LK, Gross RE: The pathogenesis and control of the hemorrhagic defect in open heart surgery. Surg Gynecol Obstet 1966;123:313-318.
30. Marin HM, Roxbury W: Hemostatic mechanism in extracorpeal circulation. Arch Surg 1964;88:988-998.
31. Kucuk O, Kwaan HC, Frederickson J, Wade L, Green D: Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol 1986;23:223-229.
32. Tice DA, Reed GE, Clauss RH, Worht MH: Hemorrhage due to fibrinolysis occurring with open-heart operations. J Thorac Cardiovasc Surg 1963;46(5):673-679.
33. Rhodes GR, Silver D: Periepicardial fibrinolytic activity: relation to cardiac bleeding. Surg 1993;78(2):230-237.
34. Moriau M, Masure R, Hurlet A, Debeys C, Chalent C, Ponlot P et al: Haemostasis disorders in open heart surgery with extracorpeal circulation. Vox Sang 1977;32: 41-51.
35. Brodsky I, Gill DN, Lusch CJ: Fibrinolysis in congenital heart disease. Am J Clin Pathol 1969;51(1):51-57.
36. Verstraete M: Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-611.
37. Ulmas J: Fibrinolysis and disseminated intravascular coagulation in open heart surgery. Transfusion 1976; 16(5):460-463.
38. Bachmann F, McKenna R, Cole ER, Najafi H: The hemostatic mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorpeal circulation. J Thorac Cardiovasc Surg 1975;70(1):76-85.
39. Vermylen J, Verstraete M, Fuster V: Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol 1986;8(6):2B-9B.
40. Adelman B, Michelson AD, Loscaizo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein IB-von Willebrand factor interactions. Blood 1985;65(1):32.
41. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R: Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388-393.
42. Musial J, Niewiarowski S, Hershock D, Morinelli TA, Coleman RW, Edmunds LH: Loss of fibrinogen receptors from the platelet surface during simulated extracorpeal circulation. J Lab Clin Med 105;4:514-522.
43. Dechavanne M, Ffrench M, Pages J, Ffrench P, Bourkerche H, Bryon PA et al.: Significant reduction in the binding of a monoclonal antibody (LYP 18) directed againsted the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorpeal circulation. Thromb Haemost 1987;57(1):106-109.
44. Oeveren WV, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-797.
45. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA: Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood 1986;68:275-280.
46. Ovrum E, Holen EA, Abdelnoor M, Oystese R, Ringdal ML: Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. J Thorac Cardiovasc Surg 1993;105(1):78-83.
47. Harder MP, Eijsman L, Roozendaal KJ, Van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991;51:936-941.
48. Horrow JC: Effective haemostasis during cardiac surgery. Can J Anaesth 1992;39(4):309-312.
49. Griffith LD, Billman GF, Daily PO, Lane TA: Apparent coagulopathy caused by infusion of shed mediastinal blood and its prevention by washing of the infusate. Ann Thorac Surg 1989;47:400-406.
50. Love TR, Hendren WG, O'Keefe DD, Daggett WM: Transfusion of predonated autologous blood in elective cardiac surgery. Ann Thorac Surg 1987;43:508-512.
51. Sterns LP, Lillehei CW: Effect of epsilon aminocaproic acid upon blood loss following open-heart surgery: an analysis of 340 patients. Can J Surg 1967;10:304-307.
52. McClure PD, Izsak J: The use of epsilon-aminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease. Anesthesiology 1974;40(6):604-608.
53. Ferraris VA, Ferraris SP, Lough FC, Berry WR: Perioperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting.
54. Horrow JC: Desmopressin and antifibrinolytics. Int Anesthesiol Clin 1990;28(4):230-236.
55. Okamoto S, Oshiba S, Okamoto M: Synthetic inhibitors of fibrinolysis: in vitro and in vivo mode of action. Ann NY Acad Sci 1972;348:415-429.
56. Westlund LE, Lunden R, Wallen P: Effect of EACA, PAMBA, AMCA, and AMBOCA on fibrinolysis induced by streptokinase, urokinase, and tissue activator. Haemostasis 1982;11:235-241.
57. Sherry S, Marder VJ: Therapy with antifibrinolytic agents. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. (Eds. Coleman RW, Hirsh J, Marder VJ, Salzman EW), Philadelphia: JP Lippincott, 1994:335-352.
58. Hoylaerts M, Lijnen HR, Collen D: Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981;673:75-85.
59. McNichol GP, Fletcher AP, Alkjaersig N, Sherry S: The absorption, distribution, and excretion of epsilon-aminocaproic acid following oral or intravenous administration to man. J Lab Clin Med 1962;59(1):15-24.
60. Lederle Laboratories: Amicar™, Aminocaproic acid. Product information. Lederle Laboratories, Pearl River, NY, September 1988.
61. Andersson L, Nilsoon IM, Collen S, Granstrand B, Melander B: Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann NY Acad Sci 1968;146(2):642-658.
62. Andersson L, Nilsoon IM, Nilehn J, Hedner U, Granstrand B, Melander B: Experimental and clinical studies of AMCA, and antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxcylic acid. Scand J Haemat 1965;2:230-247.
63. Andersson L, Eriksson O, Hedlund P, Kjellman H, Lindqvist B: Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Res 1978;6:83-88.
64. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL: The dose-response relationship of tranexamic acid. Anesthesiology 1995;82(2):383-392.
65. Nilsson IM, Andersson L, Bjorkman SL: Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 years clinical experience. Acta Med Scand 1966;448(Suppl):4-37.
66. Kane MJ, Silverman LR, Rand JH, Paciucci PA, Holland JF: Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature. Am J Med 1988;85:861-863.
67. Biswas CK, Milligan DA, Agte SD, Kenward DH, Tilley PJB: Acute renal failure and myopathy after treatment with aminocaproic acid. Brit Med J 1980;281(6233):115-116.
68. Naeye RL: Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocaproic acid. Blood 1962;19(6):694-700.
69. Clarkson AAR, Sage RE, Lawrence JR: Consumption coagulopathy and acute renal failure due to gram-negative septicemia after abortion: complete recovery with heparin therapy. Ann Intern Med 1969;70(6):1191-1198.
70. Gralnick HR, Greipp P: Thrombosis with epsilon aminocaproic acid therapy. Am J Clin Pathol 1971;56:151-154.
71. Chary tan C, Purtilo D: Glomerular capillary thrombosis and acute renal failure after epsilon-aminocaproic acid therapy. N Engl J Med 1969;280(20):1102-1104.
72. Hoffman EP, Koo AH: Cerebral thrombosis associated with Amicar therapy. Radiology 1979;131:687-689.
73. Rydin E, Lundberg PO: Tranexamic acid and intracranial thrombosis. Lancet 1976;2:49.
74. Sonntag VKH, Stein BH: Arteriopathic complications occurring during treatment of subarachnoid hemorrhage with epsilon aminocaproic acid. J Neurosurg 1974;40:480-485.
75. Vander Salm TJ, Ansell JE, Okike ON, Marsicano TH, Lew R, Stephenson WP et al.: The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: a double-blind randomized study. J Thorac Cardiovasc Surg 1988;95(3):538-540.
76. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF: Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994;108:99-108.
77. Arom KV, Emery RW: Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass. Ann Thorac Surg 1994;57: 1108-1113.
78. Horrow JC, Hlavacek J, Strong MD, Collier W, Brodsky I: Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990;99:70-74.
79. Isetta C, Samat C, Kotaiche M, Jourdan J, Grimaud D: Low dose aprotinin or tranexamic acid treatment in cardiac surgery. Anesthesiology 1991;75(Suppl):A80.
80. Horrow JC, Riper DF, Strong MD, Brodsky I, Parmet JL: Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991;84:2063-2070.
81. Nakashima A, Matsuzaki K, Fukumura F, Hisahara M, Kanegae Y: Tranexamic acid reduces blood loss after cardiopulmonary bypass. ASAIO 1993;39:M185-M189.
82. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard-Hansen P: Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108:1083-1091.
83. Fritz H, Wunderer G: Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforsch 1983;33:479-494.
84. Westaby S: Aprotinin in perspective. Ann Thorac Surg 1993;55:1033-1041.
85. Hoffman H, Siebeck M, Thetter O, Jochum M, Fritz H: Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. Adv Exp Med Biol 1989;247B:35-42.
86. Dietrich W, Spannagi M, Jochum M, Wendt P, Schramm W, Barankay A et al.: Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73(6):1119-1126.
87. Kawasuji M, Ueyama K, Sakakibara N, Tedoriya T, Matsunaga Y, Misaki T, et al: Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg 1993;55:1205-1209.
88. Havel M, Teufelsbauer H, Knobl P, Dalmatiner R, Jaksch P: Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Surg 1991;101: 968-972.
89. Beller FK, Epstein MD, Kaller H: Distribution, half-life time and placental transfer of the protease inhibitor Trasylol. J Lab Clin Med 1962;59:15-24.
90. Miles Pharmaceuticals Inc: Trasylol™, Aprotinin. Product information. Miles Pharmaceuticals Inc, West Haven, CT, January 1994.
91. Hunt BJ, Segal H, Yacoub M: Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 1992;86(Suppl 2):410-412.
92. Despotis GJ, Heinrich J, Joiner-Maier D et al: Effect of Aprotinin on activated clotting time, whole blood and plasma heparin measurements. Ann Thorac Surg 1995; 59:106-111.
93. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T: Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993;55:971-976.
94. Freeman JG, Turner GA, Venables CW, Latner AL: Serial use of aprotinin and incidence of allergic reactions. Curr Med Res Opin 1983;8(8):559-561.
95. Emerson TE Jr: Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. Cardiovasc Drug Rev 1989;7:127-140.
96. Sundt TM, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ: Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55:1418-1424.
97. Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR et al.: Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-1038.
98. Lemmer JH, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ et al.: Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-553.
99. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P: Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958-967.
100. Stern DM, Kaiser E, Nawroth PP: Regulation of the coagulation system by vascular endothelial cells. Haemostasis 1988;18:202-214.
101. Nagaoka H, Innami R, Murayama F, Funakoshi N, Hirooka K, Watanabe M et al.: Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg 1991;32:31-37.
102. Espana F, Estelles A, Griffin JH, Aznar J, Gilabert J: Aprotinin (Trasylol) is a competitive inhibitor of activated protein C. Thromb Res 1989;56:751-756.
103. Bidstrup BP, Underwood SR, Sapsford RN: Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-153.
104. Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G: Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807-810.
105. Royston D, Taylor KM, Bidstrup BP, Sapsford RN: Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;i:1289-1291.
106. Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, et al.: Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107:554-561.
107. Royston D, Bidstrup BP, Taylor KM, Sapsford RN: Reduced blood loss following open heart surgery with aprotinin (Trasylol) is associated with an increase in intraoperative clotting time. J Cardiothorac Anesth 1989;3(Suppl 1):80.
108. Bidstrup BP, Royston D, Sapsford RN, Taylor KM, Cosgrove DM: Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-372.
109. Alajmo F, Calamai G, Perna AM, Melissano G, Pretelli P: High-dose aprotinin: hemostatic effects in open heart operations. Ann Thorac Surg 1989;48:536-539.
110. Bailey CR, Wielogorski AK: Randomized placebo controlled double blind study of two low-dose aprotinin regimens in cardiac surgery. Br Heart J 1994;71:349-353.
111. Mohr R, Goor DA, Lusky A, Lavee J: Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. Circulation 1992;86(Suppl II):II-405-II-409.
112. Lavee J, Raviv Z, Smolinsky A, Savion N, Varon D: Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1993;55:114-119.
113. Carrel T, Bauer E, Laske A, von Segesser L, Turina M: Low-dose aprotinin also allows reduction of blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;102(5):801-802.
114. Cosgrove DM, Loop FD, Lytle BW, Gill CC, Golding LR: Determinants of blood utilization during myocardial revascularization. Ann Thorac Surg 1985;40(4):380-384.
115. Taylor KM: Perioperative approaches to coagulation defects. Ann Thorac Surg 1993;56(5):S78-S82.
116. Goodnaugh LT, Krushall M, Stehling L, Kennedy JM, Schwartz K, Whitsett C: A multi-center audit of transfusion practice in coronary artery bypass (CABG) surgery. Blood 1988;72(Suppl):277a.
117. Murphy JA, Smith H, Walker ID, Davidson JF: Blood transfusion in cardiac surgery. Perfusion 1990;5(Suppl): 1-7.
118. Pugh SC, Wielogorski AK: A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:240-244.
119. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA: Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995;83:679-689.
120. Alvarez JM, Quiney NF, McMillan D, Joscelyne K, Connelly T, Brady P, Deal C, Wilson R: The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:29-33.
121. Despotis GJ, Alsoufiev A Goodnough LT, Lappas DG: Aprotinin prolongs whole blood activated partial thromboplastin time but not whole blood prothrombin time in patients undergoing cardiac surgery. Anesth Analg 1995;81:919-924.
122. Jahr JS, Kaye Ad, Kang B, Feng CJ, Nossaman BD. Analysis of aprotinin on the mean arterial pressure, carotid artery blood flow and hindlimb vascular resistance in the live rat, and pulmonary vascular resistance in the isolated perfused rat lung. J Med 1995;25(1&2): 31-42.